DexCom Inc. Common Stock (DXCM)
Stock · NASDAQ · Health Care
$86.05as of 10/16/2026
Price chart
Active signals
DXCM Signal Track Record
How signals performed across all stocks →What DXCM's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 36 | -1.3% | 42% | September 8, 2026 |
| Bollinger Band Breakout | 21 | +1.3% | 57% | July 31, 2026 |
| Bollinger Band Breakdown | 20 | -0.4% | 50% | September 8, 2026 |
| 200-Day Moving Average TouchActive now | 10 | -3.7% | 30% | June 30, 2026 |
| Any 20-session window (baseline) | +0.8% | 53% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About DXCM
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems for the management of diabetes and metabolic health in the United States and internationally. The company offers Dexcom G7 and G7 15 Day, an integrated continuous glucose monitoring system; Dexcom G6, a CGM system; Dexcom ONE+ to replace fingerstick blood glucose testing for…
- Sector
- Health Care
- Industry
- Medical/Dental Instruments
- Employees
- 11,000
- Website
- www.dexcom.com/
Fundamentals
- 1-day range
- $85.43$87.88
- Market cap
- $31.33B
- P/E (trailing)
- 32.73
- P/E (forward)
- 28.08
- EPS (trailing)
- $2.51
- Dividend yield
- —
- Beta
- 1.44
- Avg. volume
- 4.40M
How DexCom Inc. Common Stock Makes Money
Where the revenue actually goes — FY2025 annual results
Source: 10-K filed Feb 12, 2026 · via SEC EDGAR / Finnhub
Forecasts
26 analyst ratings
DexCom Inc. Common Stock Competitors
Chosen by industry and closest market cap.
- DXCMDexCom Inc. Common Stock$86.04▼ 1.90%Market cap $31.33BP/E 32.73$54.11$92.59
- RMDResMed Inc. Common Stock$238.97▼ 1.35%Market cap $32.38BP/E 22.23$180.27$277.67
- WSTWest Pharmaceutical Services Inc. Common Stock$384.02▲ 0.26%Market cap $24.53BP/E 48.71$223.83$386
- MDLNMedline Inc. Class A Common Stock$35.96▼ 1.67%Market cap $45.34BP/E 69.38$31.49$50.88
- BAXBaxter International Inc. Common Stock$25.28▼ 1.86%Market cap $13.96BP/E —$15.73$30
- BDXBecton Dickinson and Company Common Stock$191.75▼ 1.04%Market cap $48.79BP/E 54.13$127.59$193.07
- GMEDGlobus Medical Inc. Class A Common Stock$76.71▼ 2.70%Market cap $11.01BP/E 19.14$56.96$101.4
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| DXCM DexCom Inc. Common Stock | $31.33B | 32.73 | $86.04 | ▼ 1.90% | $54.11$92.59 |
| RMD ResMed Inc. Common Stock | $32.38B | 22.23 | $238.97 | ▼ 1.35% | $180.27$277.67 |
| WST West Pharmaceutical Services Inc. Common Stock | $24.53B | 48.71 | $384.02 | ▲ 0.26% | $223.83$386 |
| MDLN Medline Inc. Class A Common Stock | $45.34B | 69.38 | $35.96 | ▼ 1.67% | $31.49$50.88 |
| BAX Baxter International Inc. Common Stock | $13.96B | — | $25.28 | ▼ 1.86% | $15.73$30 |
| BDX Becton Dickinson and Company Common Stock | $48.79B | 54.13 | $191.75 | ▼ 1.04% | $127.59$193.07 |
| GMED Globus Medical Inc. Class A Common Stock | $11.01B | 19.14 | $76.71 | ▼ 2.70% | $56.96$101.4 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- DexCom's CONNECT Study Published In The New England Journal Of Medicine; Findings Support The Role Of CGM Earlier In Type 2 Diabetes Care For All People, Including Those Over The Age Of 65benzinga · 10/14/2026
- Senseonics: Eversense 365 Adoption Has To Earn The ValuationSeekingAlpha · 10/8/2026
- Citi reiterates these 2 medtech stocks as its top picks in the sectorYahoo · 10/8/2026
- Intel downgraded, Marvell upgraded: Wall Street's top analyst callsYahoo · 10/7/2026
- Dexcom Schedules Third Quarter 2026 Earnings Release and Conference Call for October 29, 2026 at 4:30 p.m. Eastern TimeYahoo · 10/7/2026
- Barclays Initiates Coverage On DexCom with Overweight Rating, Announces Price Target of $115Benzinga · 10/7/2026
- Uncover the latest developments among S&P500 stocks in today's session.ChartMill · 10/6/2026
- Which S&P500 stocks are moving on Tuesday?ChartMill · 10/6/2026
- Tuesday's session: gap up and gap down stock in the S&P500 indexChartMill · 10/6/2026
Insider Activity
Insider Actions →- Nicholas Augustinos · September 15, 2026 · Sale6.5K @ $84.04
- Michael Jon Brown · September 15, 2026 · Sale1.7K @ $84.04
- Nicholas Augustinos · September 14, 2026 · Sale1.6K @ $84.02
- Jereme M. Sylvain · September 10, 2026 · Sale3.6K @ $83.27
- Glenn S. Boehnlein · September 10, 2026 · Grant5.8K
- Sadie Stern · August 27, 2026 · Sale2.6K @ $88.37
- Jacob Steven Leach · August 22, 2026 · Tax Withholding1.5K @ $92.34
- Jereme M. Sylvain · August 22, 2026 · Tax Withholding1.5K @ $92.34
- Michael Jon Brown · August 22, 2026 · Tax Withholding1.5K @ $92.34
- Sadie Stern · August 22, 2026 · Tax Withholding1.5K @ $92.34
- Kevin R. Sayer · August 20, 2026 · Sale97 @ $91.41
- Kevin R. Sayer · August 20, 2026 · Sale7.4K @ $90.78
- Kevin R. Sayer · August 20, 2026 · Sale19.3K @ $89.71
- Michael Jon Brown · August 14, 2026 · Sale1.7K @ $91.93
- Bridgette P. Heller · August 12, 2026 · Sale1.0K @ $88.29
Institutional Ownership
March 31, 2026
- Total shares held
- 341.07M
- Total value held
- $20.75B
- Institutional holders
- 947
- Unknown38.96M
- Unknown25.02M
- Unknown17.93M
- Unknown15.60M
- Unknown12.92M
- Unknown12.35M
- Unknown9.75M
- Unknown9.33M
- Unknown6.33M
- Unknown5.59M
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
DexCom CONNECT study published in NEJM
The New England Journal of Medicine published the DexCom CONNECT study, which supports using continuous glucose monitoring for people with Type 2 diabetes who do not take insulin. This finding expands the potential user base for DexCom's devices beyond insulin-dependent patients. The stock recently showed pre-market activity, and analysts maintain an average target price of $96.46.
DexCom CONNECT study published in NEJM. The New England Journal of Medicine published the DexCom CONNECT study, which supports using continuous glucose monitoring for people with Type 2 diabetes who do not take insulin. This finding expands the potential user base for DexCom's devices beyond insulin-dependent patients. The stock recently showed pre-market activity, and analysts maintain an average target price of $96.46.